Compounds as inhibitors of axl

A compound represented by Formula (I)

• or a pharmaceutically acceptable salt thereof, wherein:
• X is CR5 or N;
• G1 is N or CRG1;
• G2 is CRG2 or N;
• G3 is CRG3 or N;
• G4 is CRG4 or N;
• G5 is CRG5 or N;
• RG1 is selected from the group consisting of H, C1-3 alkyl, halogen, C1-3 haloalkyl, and CN;
• each RG2, RG3, RG4 and RG5 is independently selected from the group consisting of H, halo, CN, C1-7 alkyl, C3-7 cycloalkyl, C1-3 haloalkyl, —O—C1-3 alkyl, —O—C1-3 haloalkyl, —NRaRb, and 5- to 8-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein cycloalkyl and heterocycloalkyl are substituted with 0-3 groups independently selected from halo, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, —O—C1-4 alkyl, and OH;
• A is a fused ring selected from the group consisting of cycloheptane, cyclohexane, cyclopentane, azepane, 1,4-oxazepane, 1,4-diazepane, oxepane, tetrahydropyran, piperidine, bicyclo[4.2.1]nonane, bicyclo[4.1.1]octane, spiro[4.6]undecane, 1-azaspiro[4.6]undecane, and cyclooctane, each of which is substituted with from 1 to 4 R2, and further substituted with 0 or 1 oxo (═O) which is on a carbon atom adjacent to a nitrogen atom;
• R1 is selected from the group consisting of phenyl and a 5 to 6-membered heteroaryl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein each phenyl and heteroaryl is substituted with one R1a and 0-3 R3;
• R1a is selected from the group consisting of phenyl and a 5 to 6-membered heteroaryl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, wherein the N atom, when present, is optionally oxidized, and wherein each phenyl and heteroaryl is substituted with 0-4 R4;
• each R2 is independently selected from the group consisting of C1-7 alkyl, C3-7 alkenyl, C3-7 alkynyl, C3-7 cycloalkyl, —Y1—O—C1-7 alkyl, —Y1—O—C3-7 cycloalkyl, —NRaRb, —C(O)—C1-7 alkyl, —C(O)—C3-7 cycloalkyl, —S(O)2—C1-7 alkyl, —S(O)2—C3-7 cycloalkyl, —C(O)NRaRb, 5- to 8-membered heterocycloalkyl, —NRa-(5- to 8-membered heterocycloalkyl), —C(O)-(5- to 8-membered heterocycloalkyl), —X1-5- to 8-membered heterocycloalkyl, and —O—X1-(5- to 8-membered heterocycloalkyl), wherein the heterocycloalkyl has 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, and wherein each cycloalkyl and heterocycloalkyl is substituted with from 0-3 groups independently selected from halo, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, —O—C1-4 alkyl, and OH;
• each R3 is independently selected from the group consisting of halogen, CN, C1-7 alkyl, C2-7 alkenyl, C3-7 alkynyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 halohydroxyalkyl, —O—C1-7 alkyl, —O—C1-6 haloalkyl, —NRaRb, —C(O)—NRaRb, —S(O)2—NRaRb, —S(O)(NH)—C1-7 alkyl, —S(O)2—C1-7 alkyl, and —S(O)2—C1-7 haloalkyl;
• each R4 is independently selected from the group consisting of C1-7 alkyl, halo, C1-7 haloalkyl, —O—C1-7 alkyl, —O—C1-7 haloalkyl, CN, —C1-7 alkylene-CN, hydroxy, C1-7 hydroxyalkyl, —C(O)NRaRb, C3-7 cycloalkyl, —NRa—C(O)—C1-7 alkyl, —NRa—C(O)—C3-7 cycloalkyl, —NRaRb, —O—C1-4 alkylene-O—C1-4 alkyl, —O-(5- to 8-membered heterocycloalkyl) having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, -5- to 8-membered heterocycloalkyl having 1-3 heteroatom ring vertices selected from the group consisting of O, N, and S, —S(O)2—C1-7 alkyl, —S(O)2—C3-7 cycloalkyl, —S(O)2—NRaRb, —NRa—S(O)2—C1-7 alkyl, and —NRa—S(O)2—C3-7 cycloalkyl, wherein each cycloalkyl and heterocycloalkyl is substituted with 0 to 2 groups independently selected from the group consisting of C1-4 alkyl, halo, and hydroxy;
• alternatively, two R4 groups on the same ring vertex combine to form an oxo (═O);
• or
• two R4 groups on adjacent ring vertices combine to form a 5- to 6-membered heterocycloalkyl having from 1 to 2 heteroatom ring vertices selected from the group consisting of O, N, and S, wherein the 5- to 6-membered heterocycloalkyl is substituted with 0 to 2 groups independently selected from the group consisting of C1-4 alkyl and halo;
• R5 is selected from the group consisting of H, C1-4 alkyl, and —NH2;
• each X1 is C1-7 alkylene or C3-7 cycloalkylene;
• each Y1 is C2-7 alkylene or C3-7 cycloalkylene;
• each Ra and Rb are independently selected from group consisting of H, C1-7 alkyl, C1-7 haloalkyl, C1-4 alkoxyC1-4alkyl, C3-7 cycloalkyl, wherein said cycloalkyl is optionally substituted with —O—C1-3 alkyl;
• or
• Ra and Rb together with the nitrogen to which they are attached form a 4- to 8-membered heterocycloalkyl ring having 0-2 additional heteroatom ring vertices selected from the group consisting of O, N, and S, wherein the heterocycloalkyl ring is substituted with 0-3 groups, each group is independently selected from halo, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, —O—C1-4 alkyl, and X1—O—C1-3 alkyl, and OH;
• or two groups on the same ring vertex combine to form an oxo (═O).